Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis

Gut

Volumn 38, Issue 6, 1996, Pages 899-904

  Bertran X ^a   Mane J ^a   Fernandez Banares F ^a   Castella E ^a   Bartoli R ^a   Ojanguren, I ^a   Esteve, M ^a   Gassull, M A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

5 ASA; 5 lipoxygenase; eicosanoids; experimental colitis; trinitrobenzenesulphonic acid; zileuton

Indexed keywords

LIPOXYGENASE INHIBITOR; MESALAZINE; TRINITROBENZENESULFONIC ACID; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL AGGREGATION; CHEMOKINESIS; COLITIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ICOSANOID METABOLISM; IMMUNE RESPONSE; INTRAGASTRIC DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; WOUND HEALING;

EID: 0030016235     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.6.899     Document Type: Article

References (41)

1. Donowitz M Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway. Gastroenterology 1985; 88: 580-7.
2. Sharon P, Stenson WF Enhanced synthesis of leukotriene B by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453-60.
3. 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91: 837-44.
4. Peskar BM, Dreyling KW, Peskar BA, May B, Goebell H Enhanced formation of sulfidopeptid-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions 1986; 18: 381-3.
5. Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR. Participation of thromboxanc and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990; 98: 269-77.
6. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in rat model of inflammatory bowel disease. Gastroenterology 1989; 98: 29-36.
7. Rachmilewitz R, Simon PL, Schwartz LW, Gnswold DE, Fondacaro JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989; 97: 326-37.
8. 4 production contributes to inflammation, Gastroenterology 1987; 92: 1711.
9. Allgayer H, Stenson WF. Role of lipoxygenase pathway products in an animal model of colitis: effects of pretreatment with 5-lipoxygenase inhibitors. Gastroenterology 1988; 94: A6.
10. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 1990; 258: G527-34.
11. 4 synthesis. Gastroenterology 1992; 102: 18-27.
12. Laursen LS, Naesdal J, Bukhave K, Lauritsen K, Rask-Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335: 683-5.
13. Peppercorn M, Das K, Elson C, Geraci K, Robinson M, Rubin A, Salzberg B, Wruble L, Dube L, Rountree L, Broutman L. Zileuton, a 5-lipoxygenase inhibitor, in the treatment of active ulcerative colitis: a double-blind, placebo controlled trial. Gastroenterology 1994: A751.
14. Hawkey C, Gassull MA, Lauritsen K, Martin F, O'Morain C, Rask-Madsen J, Wright J, Dube L, Rountree L, Broutman L. Efficacy of zileuton, a 5-lipoxygenase inhibitor, in the maintenance of remission in patients with ulcerative colitis. Gastroenterology 1994; 106: A697.
15. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon, Gastroenterology 1989; 96: 795-803.
16. Vilaseca J, Salas A, Guarner F, Rodriguez R, Martinez M, Malagelada JR. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 1990; 31: 519-44.
17. Powell WS. Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples. Prostaglandins 1980; 20: 947-57.
18. Ramis I, Roselló-Catafau J, Artigot M, Bulbena O. Simultaneous reversed-phase extraction of lipoxygenase cyclooxygenase metabolites of arachidonic acid in nasal secretions; methodological aspects. J Chromatogr 1990; 532: 217-25.
19. Ramis I, Roselló-Catafau J, Gómez G, Zabay JM, Fernández-Cruz E, Gelpi E. Cyclooxygenase and lipoxygenase arachidonic acid metabolism by monocytes from human immune deficiency virus-infected drug users. J Chromatogr 1991; 557: 507-13.
20. Gelpi E, Ramis I, Hotter G, Bioque G, Bulbena O, Roselló J. Modern high-performance liquid chromatographic-radioimmunoassay strategies for the study of eicosanoids in biological samples. J Chromatogr 1989; 492: 221-50.
21. Stenson WF. Animal models of colitis. Current Opinion in Gastroenterology 1995; 11: 310-5.
22. Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid colitis in rats. Gastroenterology 1985; 88: 55-63.
23. LeDuc LE, Su KC, Guth E, Reedy T, Guth PH. Effects of cyclooxygenase and lipoxygenase inhibition on eicosanoids and healing of acetic acid colitis in rats. Dig Dis Sci 1993; 38: 289-94.
24. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638-40.
25. 2 release and its relation to discase activity, electrical potential difference and treatment in ulcerative colitis. Gut 1981; 21: 417-25.
26. 2 concentration determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 1984; 25: 1271-8.
27. Gould SR. Assay ot prostaglandin-like substances and their measurement in ulcerative colitis. Prostaglandins 1976; 11: 489-97.
28. Gould SR, Brash AR, Conolly ME, Lennard-Jones JE. Studies of prostaglandins and sulfasalazine in ulcerative colitis. Prostagladins Med 1981; 6: 165-82.
29. Kauffmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513-6.
30. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Arch Intern Med 1992; 152: 625-33.
31. 2 before and after induction os colitis with trinitrobenzenosulfonic acid in rats decreases inflammation. Gastroenterology 1989; 96: 1290-300.
32. Wallace JL, Whittle BJR, Boughton-Smith NK. Prostaglandin protection of the rat colonic mucosa from damage induced by ethanol. Dig Dis Sci 1985; 30: 866-76.
33. Yamada T, Specian RD, Granger DN, Gaginella TS, Grisham MB. Misoprostol attenuates acetic acid-induced increases in mucosal permeability and inflammation: role of blood flow. Am J Physiol 1991; 261: G332-9.
34. Zijlstra FJ, Srivastava KD, Rhodes M, van Dijk APM, Fogg F, Samson HJ, Copeman M, Russell MAH, Feyerabend C, Williams GT, Pullan RD, Thomas GAO, Van Blankenstein M, Wilson JHP, Allen A, Rhodes J. Effect of nicotine on rectal mucus and mucosal eicosanoids. Gut 1994; 35: 247-51.
35. Gryglewski RJ, Szczeklik A, Wandzilak M. The effect of six prostaglandins, prostacyclin and iloprost on generation of Superoxide anions by human polymorphonuclear leucocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol 1987; 36: 4209-12.
36. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokincs. J Immunol 1991; 146: 108-13.
37. Goto T, Herberman RB, Maluish A, Strong DM. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol 1983; 130: 1350-5.
38. Kunkel SL, Chensue SW, Phan SH. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol 1986; 136: 186-8.
39. Beno DWA, Espinal R, Edelstein BM, Davis BH. Administration of prostaglandin-E1 analog reduces rat hepatic and Ito cell collagen gene expression and collagen accumulation after bile duct ligation injury. Hepatology 1993; 17: 707-14.
40. 2 on mRNA expression and secretion of collagens I, III, and IV and fibronectine in cultured rat mesangial cells. J Am Soc Nephrol 1994; 4: 1778-85.
41. Surawicz CM, Belic C. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984; 86: 104-11.